{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:01Z","timestamp":1793381281188,"version":"4.5.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Chemerin has a potential role in perpetuating inflammation in autoimmune diseases. Nevertheless, to date, there is no conclusive information on whether high chemerin levels increase the severity of rheumatoid arthritis (RA). Therefore, this study evaluated whether serum chemerin is a biomarker of disease activity in RA patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Study design: cross-sectional. The assessment included clinical and laboratory characteristics, body mass index (BMI) and fat mass. The severity of the disease activity was identified according to the DAS28-CRP index as follows: A) RA with a DAS28-CRP\u22642.9 (remission\/mild activity) and B) RA with a DAS28-CRP&gt;2.9 (moderate\/severe activity). Serum chemerin concentrations were measured by ELISA, and \u2265103 ng\/mL was considered a high level. Logistic regression analysis was applied to determine whether high chemerin levels were associated with disease activity in RA after adjusting for confounders. Multiple regression analysis was performed to identify variables associated with chemerin levels.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Of 210 RA patients, 89 (42%) subjects had moderate\/severe disease activity and had higher serum chemerin levels than patients with low disease activity or remission (86 \u00b1 34 vs 73\u00b1 27; p = 0.003). Serum chemerin correlated with the number of swollen joints (r = 0.15; p = 0.03), DAS28-CRP (r = 0.22; p = 0.002), and C-reactive protein levels (r = 0.14; p = 0.04), but no correlation was observed with BMI and fat mass. In the adjusted logistic regression analysis, high chemerin levels (\u2265103 ng\/mL) were associated with an increased risk of moderate\/severe disease activity (OR: 2.76, 95% CI 1.35\u20135.62; p = 0.005). In the multiple regression analysis, after adjusting for potential confounders, serum chemerin levels were associated with higher DAS28-CRP (p = 0.002).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Higher chemerin levels increased the risk of moderate and severe disease activity in RA. These results support the role of chemerin as a marker of inflammation in RA. Follow-up studies will identify if maintaining low chemerin levels can be used as a therapeutic target.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0255854","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:36:14Z","timestamp":1631295374000},"page":"e0255854","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":24,"title":["Serum chemerin levels: A potential biomarker of joint inflammation in women with rheumatoid arthritis"],"prefix":"10.1371","volume":"16","author":[{"given":"Fabiola","family":"Gonzalez-Ponce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge I.","family":"Gamez-Nava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio E.","family":"Perez-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Salda\u00f1a-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Vazquez-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Ponce-Guarneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7506-1674","authenticated-orcid":true,"given":"Xochitl","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsabe","family":"Contreras-Haro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto D.","family":"Rocha-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria O.","family":"Carrillo-Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Sanchez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli E.","family":"Gomez-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Nava-Valdivia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto G.","family":"Cardona-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-6344","authenticated-orcid":true,"given":"Laura","family":"Gonzalez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Research Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"issue":"9","key":"pone.0255854.ref001","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"D Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pone.0255854.ref002","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-020-02313-w","article-title":"Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group","volume":"22","author":"I Genitsaridi","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"pone.0255854.ref003","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"DH Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"pone.0255854.ref004","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.22790","article-title":"Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate","volume":"68","author":"R Altawil","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9 Suppl B","key":"pone.0255854.ref005","doi-asserted-by":"crossref","first-page":"S09","DOI":"10.18553\/jmcp.2011.17.s9-b.S09","article-title":"Assessment of disease activity and treatment outcomes in rheumatoid arthritis","volume":"17","author":"K Farheen","year":"2011","journal-title":"J Manag Care Pharm"},{"key":"pone.0255854.ref006","doi-asserted-by":"crossref","first-page":"20587384211015034","DOI":"10.1177\/20587384211015034","article-title":"Adipokine role in physiopathology of inflammatory and degenerative musculoskeletal diseases","volume":"35","author":"L Giardullo","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"5","key":"pone.0255854.ref007","doi-asserted-by":"crossref","first-page":"R158","DOI":"10.1186\/ar3475","article-title":"Chemerin activates fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"13","author":"K Kaneko","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"pone.0255854.ref008","doi-asserted-by":"crossref","first-page":"9956","DOI":"10.1074\/jbc.M313016200","article-title":"The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency","volume":"279","author":"V Wittamer","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"pone.0255854.ref009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1248\/bpb.34.307","article-title":"Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses","volume":"34","author":"H Yamawaki","year":"2011","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"pone.0255854.ref010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.yexmp.2011.10.006","article-title":"Chemerin induces CCL2 and TLR4 in synovial fibroblasts of patients with rheumatoid arthritis and osteoarthritis","volume":"92","author":"K Eisinger","year":"2012","journal-title":"Exp Mol Pathol"},{"issue":"2","key":"pone.0255854.ref011","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jbspin.2013.07.013","article-title":"Plasma chemerin levels in rheumatoid arthritis are correlated with disease activity rather than obesity","volume":"81","author":"YJ Ha","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"2","key":"pone.0255854.ref012","doi-asserted-by":"crossref","first-page":"e57802","DOI":"10.1371\/journal.pone.0057802","article-title":"Anti-TNF therapy reduces serum levels of chemerin in rheumatoid arthritis: a new mechanism by which anti-TNF might reduce inflammation","volume":"8","author":"MM Herenius","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"pone.0255854.ref013","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10067-014-2704-1","article-title":"Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade","volume":"34","author":"K Makrilakis","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"2","key":"pone.0255854.ref014","first-page":"293","article-title":"Tocilizumab modulates serum levels of adiponectin and chemerin in patients with rheumatoid arthritis: potential cardiovascular protective role of IL-6 inhibition","volume":"37","author":"A Fioravanti","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"pone.0255854.ref015","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1038\/s41598-021-87235-6","article-title":"Functional disability is related to serum chemerin levels in rheumatoid arthritis","volume":"11","author":"ML Vazquez-Villegas","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0255854.ref016","doi-asserted-by":"crossref","first-page":"e113915","DOI":"10.1371\/journal.pone.0113915","article-title":"Association between serum chemerin concentrations and clinical indices in obesity or metabolic syndrome: a meta-analysis","volume":"9","author":"Y Li","year":"2014","journal-title":"PLoS One"},{"key":"pone.0255854.ref017","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fmed.2018.00207","article-title":"Chemerin and PEDF Are Metaflammation-Related Biomarkers of Disease Activity and Obesity in Rheumatoid Arthritis","volume":"5","author":"B Tolusso","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"pone.0255854.ref018","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5114\/reum.2020.95359","article-title":"Serum chemerin and visfatin levels and their ratio as possible diagnostic parameters of rheumatoid arthritis","volume":"58","author":"DM Mohammed Ali","year":"2020","journal-title":"Reumatologia"},{"issue":"3","key":"pone.0255854.ref019","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"FC Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"issue":"1","key":"pone.0255854.ref020","doi-asserted-by":"crossref","first-page":"e000382","DOI":"10.1136\/rmdopen-2016-000382","article-title":"DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable","volume":"3","author":"RM Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"pone.0255854.ref021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"ML Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"2","key":"pone.0255854.ref022","first-page":"117","article-title":"How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of a Spanish version of the Health Assessment Questionnaire Disability Index (Spanish HAQ-DI)","volume":"11","author":"MH Cardiel","year":"1993","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"pone.0255854.ref023","first-page":"147","article-title":"Quetelet\u2019s index (W\/H2) as a measure of fatness","volume":"9","author":"JS Garrow","year":"1985","journal-title":"Int J Obes"},{"issue":"9","key":"pone.0255854.ref024","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrrheum.2011.107","article-title":"What\u2019s new in our understanding of the role of adipokines in rheumatic diseases?","volume":"7","author":"R G\u00f3mez","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"pone.0255854.ref025","doi-asserted-by":"crossref","first-page":"425068","DOI":"10.1155\/2014\/425068","article-title":"Adipokines as potential biomarkers in rheumatoid arthritis","volume":"2014","author":"A Del Prete","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"12","key":"pone.0255854.ref026","doi-asserted-by":"crossref","first-page":"e0144932","DOI":"10.1371\/journal.pone.0144932","article-title":"Serum Vaspin Levels Are Associated with the Development of Clinically Manifest Arthritis in Autoantibody-Positive Individuals","volume":"10","author":"KI Maijer","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"pone.0255854.ref027","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4183\/aeb.2019.442","article-title":"IRISIN AND CHEMERIN LEVELS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS","volume":"15","author":"Y Akgul Balaban","year":"2019","journal-title":"Acta Endocrinol (Buchar)"},{"issue":"6","key":"pone.0255854.ref028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3346\/jkms.2016.31.6.924","article-title":"Serum Chemerin Levels Are Associated with Abdominal Visceral Fat in Type 2 Diabetes","volume":"31","author":"J Han","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"4","key":"pone.0255854.ref029","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.bbrc.2009.12.150","article-title":"Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis","volume":"391","author":"J Kaur","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"issue":"24","key":"pone.0255854.ref030","doi-asserted-by":"crossref","first-page":"16678","DOI":"10.18632\/oncotarget.24659","article-title":"Chemerin induces endothelial cell inflammation: activation of nuclear factor-kappa beta and monocyte-endothelial adhesion","volume":"9","author":"GK Dimitriadis","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"pone.0255854.ref031","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1530\/EJE-09-0380","article-title":"Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis","volume":"161","author":"M Lehrke","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1\u20133","key":"pone.0255854.ref032","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.regpep.2009.02.010","article-title":"Interleukin-1beta induces the novel adipokine chemerin in adipocytes in vitro","volume":"154","author":"S Kralisch","year":"2009","journal-title":"Regul Pept"},{"issue":"6","key":"pone.0255854.ref033","doi-asserted-by":"crossref","first-page":"R228","DOI":"10.1186\/ar3215","article-title":"Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin (21\u2013157)","volume":"12","author":"V Berg","year":"2010","journal-title":"Arthritis Res Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255854","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:36:57Z","timestamp":1631295417000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0255854"}},"subtitle":[],"editor":[{"given":"Masataka","family":"Kuwana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0255854","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]}}}